Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 198268, 15 pages
http://dx.doi.org/10.1155/2015/198268
Review Article

A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs

University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur 492010, India

Received 18 April 2015; Revised 2 June 2015; Accepted 15 June 2015

Academic Editor: Spyros S. Skandalis

Copyright © 2015 Bina Gidwani and Amber Vyas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison, “A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability,” Pharmaceutical Research, vol. 12, pp. 413–420, 1995. View at Google Scholar
  2. M. Yasir, M. Asif, A. Kumar, and A. Aggarval, “Biopharmaceutical classification system: an account,” International Journal of PharmTech Research, vol. 2, no. 3, pp. 1681–1690, 2010. View at Google Scholar · View at Scopus
  3. T. Loftsson, M. E. Brewster, and M. Másson, “Role of cyclodextrins in improving oral drug delivery,” The American Journal of Drug Delivery, vol. 2, no. 4, pp. 261–275, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. J. M. M. Terwogt, J. H. M. Schellens, W. W. Ten Bokkel Huinink, and J. H. Beijnen, “Clinical pharmacology of anticancer agents in relation to formulations and administration routes,” Cancer Treatment Reviews, vol. 25, no. 2, pp. 83–101, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Ran, A. Jain, and S. H. Yalkowsky, “Solubilization and preformulation studies on PG-300995 (an anti-HIV drug),” Journal of Pharmaceutical Sciences, vol. 94, no. 2, pp. 297–303, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. F. A. A. Nunez and S. H. Yalkowsky, “Solubilization of diazepam,” Journal of Pharmaceutical Science and Technology, vol. 52, pp. 33–36, 1998. View at Google Scholar
  7. S. K. Han, G. Y. Kim, and Y. H. Park, “Solubilization of biphenyl dimethyl dicarboxylate by cosolvency,” Drug Development and Industrial Pharmacy, vol. 25, no. 11, pp. 1193–1197, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. A. T. M. Serajuddln, “Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs,” Journal of Pharmaceutical Sciences, vol. 88, no. 10, pp. 1058–1066, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Leuner and J. Dressman, “Improving drug solubility for oral delivery using solid dispersions,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 47–60, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Breitenbach, “Melt extrusion: from process to drug delivery technology,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 54, no. 2, pp. 107–117, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. M. N. Reddy, T. Rehana, S. Ramakrishna, K. P. R. Chowdary, and P. V. Diwan, “β-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies,” AAPS PharmSciTech, vol. 6, no. 1, pp. 68–76, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. L.-P. Ruan, B.-Y. Yu, G.-M. Fu, and D.-N. Zhu, “Improving the solubility of ampelopsin by solid dispersions and inclusion complexes,” Journal of Pharmaceutical and Biomedical Analysis, vol. 38, no. 3, pp. 457–464, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Radtke, “Pure drug nanoparticles for the formulation of poorly soluble drugs,” New Drugs, vol. 3, Article ID 68, pp. 62–68, 2001. View at Google Scholar
  14. R. H. Müller, C. Jacobs, and O. Kayser, “Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future,” Advanced Drug Delivery Reviews, vol. 47, no. 1, pp. 3–19, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Merisko-Liversidge, G. G. Liversidge, and E. R. Cooper, “Nanosizing: a formulation approach for poorly-water-soluble compounds,” European Journal of Pharmaceutical Sciences, vol. 18, no. 2, pp. 113–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Vyas, S. Saraf, and S. Saraf, “Cyclodextrin based novel drug delivery systems,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 62, no. 1-2, pp. 23–42, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Karande and S. Mitragotri, “Enhancement of transdermal drug delivery via synergistic action of chemicals,” Biochimica et Biophysica Acta—Biomembranes, vol. 1788, no. 11, pp. 2362–2373, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Manosroi, M. G. Apriyani, K. Foe, and A. Manosroi, “Enhancement of the release of azelaic acid through the synthetic membranes by inclusion complex formation with hydroxypropyl-beta-cyclodextrin,” International Journal of Pharmaceutics, vol. 293, no. 1-2, pp. 235–240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Hirayama, S. Mieda, Y. Miyamoto, H. Arima, and K. Uekama, “Heptakis(2,6-di-O-methyl-3-O-acetyl)-β-cyclodextrin: a water-soluble cyclodextrin derivative with low hemolytic activity,” Journal of Pharmaceutical Sciences, vol. 88, no. 10, pp. 970–975, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Ono, H. Arima, F. Hirayama, and K. Uekama, “A moderate interaction of maltosyl-α-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin,” Biological and Pharmaceutical Bulletin, vol. 24, no. 4, pp. 395–402, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. K. H. Froomming and J. Szejtli, Cyclodextrins in Pharmacy, Kluwer Academic Publishers, Dortrecht, The Netherlands, 1994.
  22. A. Al-Omar, S. Abdou, L. de Robertis, A. Marsura, and C. Finance, “Complexation study and anticellular activity enhancement by doxorubicin-cyclodextrin complexes on a multidrug-resistant adenocarcinoma cell line,” Bioorganic and Medicinal Chemistry Letters, vol. 9, no. 8, pp. 1115–1120, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. J. J. García-Rodriguez, J. Torrado, and F. Bolás, “Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes,” Parasite, vol. 8, no. 2, pp. S188–S190, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. J. P. Donnelly and B. E. de Pauw, “Voriconazole—a new therapeutic agent with an extended spectrum of antifungal activity,” Clinical Microbiology and Infection, vol. 10, no. 1, pp. 107–117, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Kim, “Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether,” Journal of Pharmaceutical Sciences, vol. 87, no. 12, pp. 1560–1567, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Uekama, M. Otagiri, T. Irie, H. Seo, and M. Tsuruoka, “Improvement of dissolution and absorption characteristics of phenytoin by a water-soluble β-cyclodextrin-epichlorohydrin polymer,” International Journal of Pharmaceutics, vol. 23, no. 1, pp. 35–42, 1985. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Gidwani and A. Vyas, “Synthesis, characterization and application of epichlorohydrin-β-cyclodextrin polymer,” Colloids and Surfaces B: Biointerfaces, vol. 114, pp. 130–137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Szeman, H. Ueda, J. Szejtli, E. Fenyvesi, Y. Machida, and T. Nagai, “Complexation of several drugs with water-soluble cyclodextrin polymer,” Chemical and Pharmaceutical Bulletin, vol. 35, no. 1, pp. 282–288, 1987. View at Publisher · View at Google Scholar · View at Scopus
  29. É. Fenyvesi, “Cyclodextrin polymers in the pharmaceutical industry,” Journal of Inclusion Phenomena, vol. 6, no. 5, pp. 537–545, 1988. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Szente and J. Szejtli, “Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development,” Advanced Drug Delivery Reviews, vol. 36, no. 1, pp. 17–28, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. A. M. Layre, N. M. Gosselet, E. Renard, B. Sebille, and C. Amiel, “Comparison of the complexation of cosmetic and pharmaceutical compounds with β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin and water-soluble-β-cyclodextrin-co-epichlorohydrin polymers,” Journal of Inclusion Phenomenon and Macrocyclic Chemistry, vol. 43, pp. 311–317, 2002. View at Google Scholar
  32. J. Szejtli, Cyclodextrins and Their Inclusion Complexes, Akadémiai Kiadó, Budapest, Hungary, 1982.
  33. R. Challa, A. Ahuja, J. Ali, and R. K. Khar, “Cyclodextrins in drug delivery: an updated review,” AAPS PharmSciTech, vol. 6, no. 2, pp. E329–E357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. Â. M. L. Denadai, M. M. Santoro, M. T. P. Lopes et al., “A supramolecular complex between proteinases and beta-cyclodextrin that preserves enzymatic activity,” BioDrugs, vol. 20, no. 5, pp. 283–291, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Szente, J. Szejtli, and G. L. Kis, “Spontaneous opalescence of aqueous γ-cyclodextrin solutions: complex formation or self-aggregation?” Journal of Pharmaceutical Sciences, vol. 87, no. 6, pp. 778–781, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. M. E. Cortés, R. D. Sinisterra, M. J. Avila-Campos, N. Tortamano, and R. G. Rocha, “The chlorhexidine: β-cyclodextrin inclusion compound: preparation, characterization and microbiological evaluation,” Journal of Inclusion Phenomenon and Macrocyclic Chemistry, vol. 40, no. 4, pp. 297–302, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. E. M. M. Del Valle, “Cyclodextrins and their uses: a review,” Process Biochemistry, vol. 39, no. 9, pp. 1033–1046, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Dodziuk, “Rigidity versus flexibility. A review of experimental and theoretical studies pertaining to the cyclodextrin nonrigidity,” Journal of Molecular Structure, vol. 614, no. 1–3, pp. 33–45, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Szejtli, “Introduction and general overview of cyclodextrin chemistry,” Chemical Reviews, vol. 98, no. 5, pp. 1743–1753, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. R. A. Rajewski and V. J. Stella, “Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery,” Journal of Pharmaceutical Sciences, vol. 85, no. 11, pp. 1142–1168, 1996. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Zhang, C. Q. Lan, M. Post, B. Simard, Y. Deslandes, and T. H. Hsieh, “Design of nanoparticles as drug carriers for cancer therapy,” Cancer Genomics & Proteomics, vol. 3, no. 3-4, pp. 147–157, 2006. View at Google Scholar · View at Scopus
  42. G. S. Kwon, “Polymeric micelles for delivery of poorly water-soluble compounds,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 20, no. 5, pp. 357–403, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Luo and G. D. Prestwich, “Cancer-targeted polymeric drugs,” Current Cancer Drug Targets, vol. 2, no. 3, pp. 209–226, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Nie, Y. Xing, G. J. Kim, and J. W. Simons, “Nanotechnology applications in cancer,” Annual Review of Biomedical Engineering, vol. 9, no. 1, pp. 257–288, 2007. View at Publisher · View at Google Scholar
  45. Y. Jiang, X. Jiang, K. Law et al., “Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation,” International Journal of Pharmaceutics, vol. 415, no. 1-2, pp. 252–258, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. U. V. Singh, K. S. Aithal, and N. Udupa, “Physicochemical and biological studies of inclusion complex of methotrexate with β-cyclodextrin,” Pharmaceutical Sciences, vol. 3, no. 12, pp. 573–577, 1997. View at Google Scholar · View at Scopus
  47. M. Lahiani-Skiba, F. Bounoure, H. Fessi, and M. Skiba, “Effect of cyclodextrins on lonidamine release and in-vitro cytotoxicity,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 69, no. 3-4, pp. 481–485, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Yavuz, E. Bilensoy, I. Vural, and M. Şumnu, “Alternative oral exemestane formulation: improved dissolution and permeation,” International Journal of Pharmaceutics, vol. 398, no. 1-2, pp. 137–145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Y. Cai, C. W. Yap, and Z. Wang, “Solubilization of vorinostat by cyclodextrins,” Journal of Clinical and Pharmaceutical Therapeutics, vol. 34, pp. 1–6, 2009. View at Google Scholar
  50. S. Béni, Z. Szakács, O. Csernák, L. Barcza, and B. Noszál, “Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities,” European Journal of Pharmaceutical Sciences, vol. 30, no. 2, pp. 167–174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Peng, Y. Liu, H. Zhang, Y. Cui, G. Zhai, and C. Chen, “Photostability study of doxorubicin aqueous solution enhanced by inclusion interaction between doxorubicin and hydroxypropyl-β-cyclodextrin,” Chinese Journal of Chemistry, vol. 28, no. 7, pp. 1291–1295, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Balaji, V. P. Pandey, M. S. Srinath, and R. Manavalan, “Synthesis and characterization studies of cisplatin/hydroxypropyl-β-cyclodextrin complex,” Pharmacologyonline, vol. 1, pp. 1135–1143, 2009. View at Google Scholar · View at Scopus
  53. N. Elgindy, K. Elkhodairy, A. Molokhia, and A. Elzoghby, “Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug, flutamide,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 74, no. 2, pp. 397–405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. E. E. M. Eid, A. B. Abdul, F. E. O. Suliman, M. A. Sukari, A. Rasedee, and S. S. Fatah, “Characterization of the inclusion complex of zerumbone with hydroxypropyl-β-cyclodextrin,” Carbohydrate Polymers, vol. 83, no. 4, pp. 1707–1714, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Q. Ma, R. A. Rajewski, and V. J. Stella, “New injectable melphalan formulations utilizing (SBE)7m-β-CD or HP-β-CD,” International Journal of Pharmaceutics, vol. 189, no. 2, pp. 227–234, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Li, S. Wang, J. Gao, and S. Fang, “Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats,” National Journal of Physiology, Pharmacy and Pharmacology, vol. 2, pp. 52–57, 2012. View at Google Scholar
  57. E. Bilensoy, Y. Çirpanli, M. Şen, A. L. Doǧan, and S. Çaliş, “Thermosensitive mucoadhesive gel formulation loaded with 5-Fu: cyclodextrin complex for HPV-induced cervical cancer,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 57, no. 1–4, pp. 363–370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. V. Monnaert, D. Betbeder, L. Fenart et al., “Effects of γ- and hydroxypropyl-γ-cyclodextrins on the transport of doxorubicin across an in vitro model of blood-brain barrier,” Journal of Pharmacology & Experimental Therapeutics, vol. 311, no. 3, pp. 1115–1120, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Arima, Y. Hagiwara, F. Hirayama, and K. Uekama, “Enhancement of antitumor effect of doxorubicin by its complexation with γ-cyclodextrin in pegylated liposomes,” Journal of Drug Targeting, vol. 14, no. 4, pp. 225–232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. S. S. Dhule, P. Penfornis, T. Frazier et al., “Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma,” Nanomedicine, vol. 8, no. 4, pp. 440–451, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Oommen, S. P. B. Tiwari, N. Udupa, R. Kamath, and P. U. Devi, “Niosome entrapped β-cyclodextrin methotrexate complex as a drug delivery system,” Indian Journal of Pharmacology, vol. 31, no. 4, pp. 279–284, 1999. View at Google Scholar · View at Scopus
  62. S. Swaminathan, L. Pastero, L. Serpe et al., “Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 74, no. 2, pp. 193–201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. B. Mognetti, A. Barberis, S. Marino et al., “In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 74, no. 1–4, pp. 201–210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Liu, X. Li, Y. Qian, X. Hu, and S. Liu, “Multifunctional pH-disintegrable micellar nanoparticles of asymmetrically functionalized β-cyclodextrin-based star copolymer covalently conjugated with doxorubicin and DOTA-Gd moieties,” Biomaterials, vol. 33, no. 8, pp. 2521–2531, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Wang, E. Blanco, J. Gao, H. Ai, and D. A. Boothman, “Modulating β-lapachone release from polymer millirods through cyclodextrin complexation,” Journal of Pharmaceutical Sciences, vol. 95, no. 10, pp. 2309–2319, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Çirpanli, E. Bilensoy, A. L. Doğan, and S. Çaliş, “Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 73, no. 1, pp. 82–89, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Agüeros, L. Ruiz-Gatón, C. Vauthier et al., “Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel,” European Journal of Pharmaceutical Sciences, vol. 38, no. 4, pp. 405–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Quaglia, L. Ostacolo, A. Mazzaglia, V. Villari, D. Zaccaria, and M. T. Sciortino, “The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs,” Biomaterials, vol. 30, no. 3, pp. 374–382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Kreuter, Nanoparticles: Colloidal Drug Delivery Systems, Marcel Dekker, New York, NY, USA, 1994.
  70. I. Brigger, C. Dubernet, and P. Couvreur, “Nanoparticles in cancer therapy and diagnosis,” Advanced Drug Delivery Reviews, vol. 54, no. 5, pp. 631–651, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. A. A. Stavrovskaya, “Cellular mechanisms of multidrug resistance of tumor cells,” Biochemistry, vol. 65, no. 1, pp. 95–106, 2000. View at Google Scholar · View at Scopus
  72. C. Moorthi, R. Manavalan, and K. Kathiresan, “Nanotherapeutics to overcome conventional cancer chemotherapy limitations,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 14, no. 1, pp. 67–77, 2011. View at Google Scholar · View at Scopus
  73. T. Lammers, W. E. Hennink, and G. Storm, “Tumour-targeted nanomedicines: principles and practice,” British Journal of Cancer, vol. 99, no. 3, pp. 392–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, “Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review,” Journal of Controlled Release, vol. 65, no. 1-2, pp. 271–284, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. F. J. Otero-Espinar, J. J. Torres-Labandeira, C. Alvarez-Lorenzo, and J. Blanco-Méndez, “Cyclodextrins in drug delivery systems,” Journal of Drug Delivery Science and Technology, vol. 20, no. 4, pp. 289–301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Maeda, G. Y. Bharate, and J. Daruwalla, “Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 71, no. 3, pp. 409–419, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. V. J. Stella and Q. He, “Cyclodextrins,” Toxicologic Pathology, vol. 36, no. 1, pp. 30–42, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Agrawal and V. Gupta, “Cyclodextrins—a review on pharmaceutical application for drug delivery,” International Journal of Pharmaceutical Frontier Research, vol. 2, no. 1, pp. 95–112, 2012. View at Google Scholar
  79. B. McCormack and G. Gregoriadis, “Comparative studies of the fate of free and liposome-entrapped hydroxypropyl-β-cyclodextrin/drug complexes after intravenous injection into rats: implications in drug delivery,” Biochimica et Biophysica Acta: General Subjects, vol. 1291, no. 3, pp. 237–244, 1996. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Cui, C. Li, C. Wang et al., “Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?” Journal of Pharmaceutical Sciences, vol. 100, no. 7, pp. 2835–2848, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Sankhyan and P. Pawar, “Recent trends in niosome as vesicular drug delivery system,” Journal of Applied Pharmaceutical Science, vol. 2, no. 6, pp. 20–32, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Cavalli, F. Trotta, and W. Tumiatti, “Cyclodextrin-based nanosponges for drug delivery,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 56, no. 1-2, pp. 209–213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Oerlemans, W. Bult, M. Bos, G. Storm, J. F. W. Nijsen, and W. E. Hennink, “Polymeric micelles in anticancer therapy: targeting, imaging and triggered release,” Pharmaceutical Research, vol. 27, no. 12, pp. 2569–2589, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Wang, G. M. Saidel, and J. Gao, “A mechanistic model of controlled drug release from polymer millirods: effects of excipients and complex binding,” Journal of Controlled Release, vol. 119, no. 1, pp. 111–120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. X. Zhang, X. Zhang, Z. Wu et al., “A hydrotropic β-cyclodextrin grafted hyperbranched polyglycerol co-polymer for hydrophobic drug delivery,” Acta Biomaterialia, vol. 7, no. 2, pp. 585–592, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Zeng, H. Hunag, and S. Liu, “Hollow nanospheres fabricated from β-cyclodextrin-grafted α, β-poly (aspartic acid) as the carrier of camptothecin,” Colloids and Surfaces B: Biointerfaces, vol. 105, pp. 120–127, 2013. View at Google Scholar
  87. A. Z. M. Badruddoza, M. T. Rahman, S. Ghosh et al., “β-Cyclodextrin conjugated magnetic, fluorescent silica core-shell nanoparticles for biomedical applications,” Carbohydrate Polymers, vol. 95, no. 1, pp. 449–457, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Sahu and S. Mohapatra, “Multifunctional magnetic fluorescent hybrid nanoparticles as carriers for the hydrophobic anticancer drug 5-fluorouracil,” Dalton Transactions, vol. 42, no. 6, pp. 2224–2231, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Silambarasi, S. Latha, M. Thambidurai, and P. Selvamani, “Formulation and evaluation of curcumin loaded magnetic nanoparticles for cancer therapy,” International Journal of Pharmaceutical Sciences and Research, vol. 3, no. 5, pp. 1393–1400, 2012. View at Google Scholar
  90. K. Chaturvedi, K. Ganguly, A. R. Kulkarni et al., “Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review,” Expert Opinion on Drug Delivery, vol. 8, no. 11, pp. 1455–1468, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. C. Kim, B. P. Shah, P. Subramaniam, and K.-B. Lee, “Synergistic induction of apoptosis in brain cancer cells by targeted co-delivery of siRNA and anticancer drugs,” Molecular Pharmaceutics, vol. 8, no. 5, pp. 1955–1961, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Deng, N. Li, K. Mai, C. Yang, L. Yan, and L.-M. Zhang, “Star-shaped polymers consisting of a β-cyclodextrin core and poly(amidoamine) dendron arms: binding and release studies with methotrexate and siRNA,” Journal of Materials Chemistry, vol. 21, no. 14, pp. 5273–5281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. D. A. Scheinberg, T. L. Rosenblat, and J. G. Jurcic, “Antibodies,” in Chemotherapy and Biotherapy: Principles and Practice, B. A. Chabner and D. L. Longo, Eds., pp. 465–494, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 5th edition, 2011. View at Google Scholar
  94. M. Beeram, H. A. Burris, S. Modi, and M. Beeram, “A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate (ADC), given every 3 weeks to patients with HER2+ metastatic breast cancer,” in Proceedings of the American Society Clinical Oncology Annual Meeting, May 2008.
  95. H. A. Burris, S. Vukelja, and H. S. Rugo, “A phase II study of trastuzumab-DM1(T-DM1), a HER2 antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer,” in Proceedings of the ASCO Breast Cancer Symposium, 2008.
  96. S. N. Holden, M. Beeram, and I. E. Krop, “A phase I study of weekly dosing of trastuzumab-DM1(T-DM1) in patients with advanced HER2+ breast cancer,” in Proceedings of the American Society Clinical Oncology Annual Meeting, 2008.
  97. M. F. Press, C. Cordon-Cardo, and D. J. Slamon, “Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues,” Oncogene, vol. 5, no. 7, pp. 953–962, 1990. View at Google Scholar · View at Scopus
  98. G. D. L. Phillips, G. Li, D. L. Dugger et al., “Targeting HER2-positive breast cancer with trastuzumab–DM1, an antibody–cytotoxic drug conjugate,” Cancer Research, vol. 68, no. 22, pp. 9280–9290, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Boyiadzis and K. A. Foon, “Approved monoclonal antibodies for cancer therapy,” Expert Opinion on Biological Therapy, vol. 8, no. 8, pp. 1151–1158, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. B. M. Boman and M. S. Wicha, “Cancer stem cells: a step toward the cure,” Journal of Clinical Oncology, vol. 26, no. 17, pp. 2795–2799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. O. K. Okamoto and J. F. Perez, “Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis,” Expert Review of Molecular Diagnostics, vol. 8, no. 4, pp. 387–393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. K. Ikura, J.-I. Fujimoto, K. Kubonishi et al., “A monoclonal antibody to cyclomaltoheptaose (β-cyclodextrin): characterization and use for immunoassay of β-cyclodextrin and its derivatives,” Cytotechnology, vol. 40, no. 1–3, pp. 23–29, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. T. G. Johns, R. B. Luwor, C. Murone et al., “Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15871–15876, 2003. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Harada, Y. Takashima, and H. Yamaguchi, “Cyclodextrin-based supramolecular polymers,” Chemical Society Reviews, vol. 38, no. 4, pp. 875–882, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Li, “Self-assembled supramolecular hydrogels based on polymer-cyclodextrin inclusion complexes for drug delivery,” NPG Asia Materials, vol. 2, no. 3, pp. 112–118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Pourjavadi, M. Adeli, and M. Yazdi, “Fully supramolecular vesicles as anticancer drug delivery systems,” New Journal of Chemistry, vol. 37, no. 2, pp. 295–298, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. D. Paolino, M. Licciardi, C. Celia, G. Giammona, M. Fresta, and G. Cavallaro, “Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 82, no. 1, pp. 94–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. R. B. Walter, B. W. Raden, D. M. Kamikura, J. A. Cooper, and I. D. Bernstein, “Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity,” Blood, vol. 105, no. 3, pp. 1295–1302, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. K. Takara, T. Sakaeda, and K. Okumura, “An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy,” Current Pharmaceutical Design, vol. 12, no. 3, pp. 273–286, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Ishikawa, H. Yoshii, and T. Furuta, “Interaction of modified cyclodextrins with cytochrome P-450,” Bioscience, Biotechnology and Biochemistry, vol. 69, no. 1, pp. 246–248, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. R. G. Strickley, “Solubilizing excipients in oral and injectable formulations,” Pharmaceutical Research, vol. 21, no. 2, pp. 201–230, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. S. Shimpi, B. Chauhan, and P. Shimpi, “Cyclodextrins: application in different routes of drug administration,” Acta Pharmaceutica, vol. 55, no. 2, pp. 139–156, 2005. View at Google Scholar · View at Scopus
  113. E. Oommen, B. D. Shenoy, N. Udupa, R. Kamath, and P. U. Devi, “Antitumour efficacy of cyclodextrin-complexed and niosome-encapsulated plumbagin in mice bearing melanoma B16F1,” Pharmacy and Pharmacology Communications, vol. 5, no. 4, pp. 281–285, 1999. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Glucksmann, L. A. Reiter, and T. C. Crawford, “Cyclodextrin-based polymers for therapeutic delivery,” US20120202772 A1, 2012.